



**Figura 1.** Resonancia magnética nuclear craneal.

visuales, cefalea y convulsiones, pero se resolvieron en un máximo de 3 semanas sin secuelas ni recidivas al controlar la TA y, en el primer caso, modificar el tratamiento inmunosupresor. En nuestro caso, la paciente debutó a los 4 meses de haber presentado la enfermedad, cuando sus anticuerpos anti-MBG se habían negativizado y sin tratamiento inmunosupresor activo.

En este contexto resulta especialmente importante el control de la HTA para prevenir un cuadro grave que, aunque de curso generalmente benigno, puede provocar una encefalopatía potencialmente severa.

#### Conflictos de interés

Los autores declaran que no tienen conflictos de interés potenciales relacionados con los contenidos de este artículo.

1. Hinckley J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med* 1996;334:494-500.
2. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. *Mayo Clin Proc* 2010;85:427-32.
3. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of

reversible posterior leukoencephalopathy syndrome. *Arch Neurol* 2008;65:205-10.

4. Abenza-Abildua MJ, Fuentes B, Diaz D, Royo A, Olea T, Aguilar-Amat MJ, et al. Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome. *BMJ Case Rep* 2009;2009. pii: bcr07.2008.0467. Epub 2009 May 25.
5. Ozkok A, Elcioglu OC, Bakan A, Atilgan KG, Alisir S, Odabas AR. Reversible posterior leukoencephalopathy in the course of goodpasture syndrome. *Ren Fail* 2012;34(2):254-6.

**M. José Gutiérrez-Sánchez, Vladimir Petkov-Stoyanov, Juan A. Martín-Navarro**

Sección de Nefrología.

Hospital del Tajo. Aranjuez, Madrid.

**Correspondencia:** Juan A. Martín Navarro  
Sección de Nefrología.

Hospital del Tajo, Avda. Amazonas Central, s/n.  
28300 Aranjuez, Madrid.  
[juanmartinnav@hotmail.com](mailto:juanmartinnav@hotmail.com)

## Catheter-related relapsing peritonitis due to *Kocuria varians* in a patient undergoing Continuous Ambulatory Peritoneal Dialysis

*Nefrologia* 2012;32(4):541-2

doi:10.3265/Nefrologia.pre2012.Apr.11471

#### Dear Editor,

*Kocuria varians* is a Gram positive non-pathogenic commensal of the mammalian skin that can be present also in soil and water. *Kocuria* spp. was previously classified in the genus *Micrococcus*<sup>1</sup> and identification of the species by automated systems has been reported to be problematic.<sup>2</sup> Published cases of infections caused by *Kocuria varians* in the English literature are rare and consider patients with serious underlying disease.<sup>3</sup> We report here a case of relapsing peritonitis in a patient undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) that was

**Tabla 1.** Causas del síndrome de leuкоencefalopatía posterior reversible.

- Encefalopatía hipertensiva (HTA inducida por embarazo, HTA maligna)
- Eclampsia
- Insuficiencia renal aguda o crónica
- Insuficiencia hepática aguda
- Sepsis
- Vasculitis y enfermedades autoinmunes: LES, PAN, Wegener, ESP, EMTC, dermatomiositis, poliangeitis microscópica, Schönlein-Henoch, crioglobulinemia
- Enfermedades hematológicas: SHU, PTT, anemia drepanocítica, enfermedades linfoproliferativas
- Porfiria aguda intermitente
- Alteraciones iónicas: hipomagnesemia, hipocalcemia
- Transfusiones sanguíneas
- Exposición a contrastes intravenosos
- Inmunosupresores y citotóxicos: anfotericina B, bevacizumab, altas dosis de corticoides, cisplatino, metotrexate, quimioterapia combinada (CHOP), ciclosporina, citarabina, gencitabina, interferón alfa, inmunoglobulinas intravenosa, metotrexate, rituximab, sirolimus, sorafenib, sunitinib, tacrolimus y vincristina
- Crisis epilépticas prolongadas
- Tratamiento con eritropoyetina
- Primoinfección por VIH

CHOP: ciclofosfamida, doxorubicina, vincristina y prednisolona; EMTC: enfermedad mixta del tejido conectivo; ESP: esclerosis sistémica progresiva; HTA: hipertensión arterial; LES: lupus eritematoso sistémico; PAN: poliarteritis nodosa; PTT: púrpura trombocitopénica trombótica; SHU: síndrome hemolítico urémico; VIH: virus de la inmunodeficiencia humana.

resolved after catheter removal.

The patient, a 70-year-old man with chronic renal failure and class III heart failure was admitted to the hospital on 26 July 2010 with turbid peritoneal dialysate, non febrile, having mild abdominal pain and positive Rebound sign at the physical examination. Leucocyte cell count showed the presence of 1200 leucocytes/ $\mu$ l (neutrophil count of 90%) in the peritoneal dialysate but subsequent culture of the fluid resulted negative. Treatment started with vancomycin 15mg/kg/5 days i.p. and aztreonam 2gr/d i.p. for a total of 20 days. On 30 July 2010 cell count was 50 leucocytes/ $\mu$ l and the patient was discharged.

3 days later however, at the first control visit, the peritoneal dialysate was turbid anew, the patient presented the same clinical findings and cell count revealed the presence of 300 leucocytes/ $\mu$ l. A Gram positive, spherical microorganism that occurred in tetrads with circular, smooth, glistening and yellow colonies was recovered from the peritoneal dialysate. The microorganism was identified as *Kocuria varians* by the VITEK 2 system. The isolate was susceptible to gentamycin, erythromycin, clindamycin, tetracycline, glycopeptides and linezolid while it was resistant to levofloxacin by the disc diffusion method. Following laboratory report, the patient was treated with vancomycin alone (15mg/kg/5 days i.p. for a total of 20 days).

Turbidity of the peritoneal dialysate did not reappear until 27 August 2010 when the patient was admitted to the hospital with generalized abdominal pain, positive Rebound sign and cell count of 550 leucocytes/ $\mu$ l. *K. varians* was isolated for the second time and removal of the peritoneal catheter followed by insertion of a new one in a different position was considered. Culture of the removed catheter was positive for *K. varians*. Vancomycin i.p. was administered, subsequent cultures were negative and the patient

remained in good clinical condition since then.

Infections related to *K. varians* are uncommon but this species may act as opportunistic pathogen in immunocompromised patients with underlying diseases. Furthermore, *K. varians* is a biofilm forming bacterium<sup>4</sup> thus probably complicating the antimicrobial treatment of catheter related infections. Erroneous identification of coagulase-negative Staphylococci as *Kocuria* spp. is possible and can be excluded with certainty only with the application of genotypic assays such as 16S RNA.<sup>1</sup> In the present case the Vitek 2 system using the new GP identification card<sup>5</sup> reported a “very good identification” for all three isolations. This case report aims on emphasizing the importance of careful consideration of the laboratory and clinical procedures when rarely pathogenic microorganisms are isolated in the peritoneal dialysate of patients undergoing CAPD.

### Conflicts of interest

The authors declare that there is no conflict of interest associated with this manuscript.

1. Stackebrandt E, Koch C, Gvozdiak O, Schumann P. Taxonomic dissection of the genus Micrococcus: *Kocuria* gen. nov., *Nesterenkonia* gen. nov., *Kytococcus* gen. nov., *Dermacoccus* gen. nov., and *Micrococcus* Cohn 1872 gen. emend. Int J Syst Bacteriol 1995;45:682-92.
2. Ben-Ami R, Navon-Venezia S, Schwartz D, Schlezinger Y, Mekuzas Y, Carmeli Y. Erroneous reporting of coagulase-negative Staphylococci as *Kocuria* spp. by the Vitek 2 system. J Clin Microbiol 2005;43:1448-50.
3. Tsai CY, Su SH, Cheng YH, Chou YL, Tsai TH, Lieu AS. *Kocuria varians* infection associated with brain abscess: A case report. BMC Infect Dis 2010;10:102.
4. Midelet G, Kobilinsky A, Carpentier B. Construction and analysis of fractional multifactorial designs to study attachment strength and transfer of *Listeria monocytogenes* from pure or

mixed biofilms after contact with a solid model food. Appl Environ Microbiol 2006;72:2313-21.

5. Boudewijns M, Vandeven J, Verhaegen J, Ben-Ami R, Carmeli Y. Vitek 2 automated identification system and *Kocuria* kristinae. J Clin Microbiol 2005;43:5832.

**Georgios Meletis<sup>1</sup>, Vasiliki Gogou<sup>1</sup>, Maria Palamouti<sup>1</sup>, Petros Spiropoulos<sup>2</sup>, Kiriaki Xanthopoulou<sup>2</sup>, Paraskevi Tantou<sup>1</sup>, Artemisia Rizou<sup>1</sup>, Vasileios Thomoglou<sup>1</sup>**

<sup>1</sup> Department of Clinical Microbiology. Veroia G. Hospital. Veroia (Greece).

<sup>2</sup> Nephrology Department. Veroia G. Hospital. Veroia (Greece).

**Correspondence:** Georgios Meletis  
Department of Clinical Microbiology.  
Veroia G. Hospital, Veroia, Greece.  
meletisg@hotmail.com

## Enfermedad de Paget poliostótica asintomática asociada a hiperparatiroidismo secundario en un paciente en diálisis peritoneal

Nefrologia 2012;32(4):542-4

doi:10.3265/Nefrologia.pre2012.Apr.11477

### Sr. Director:

La enfermedad ósea de Paget (EP) es un trastorno focal del remodelado óseo que puede afectar a uno o más huesos<sup>1</sup>. Es la segunda patología ósea más frecuente después de la osteoporosis y su diagnóstico en la mayoría de los casos se realiza mediante una bioquímica rutinaria, donde se aprecia elevación de la fosfatasa alcalina (FA), o en estudios de imagen realizados por otros motivos<sup>1,3</sup>.

Su incidencia en pacientes con enfermedad renal crónica (ERC) es desconocida. Pocos han sido los casos comunicados en la literatura<sup>4-8</sup>, y en algunos de ellos la presencia de EP se ve enmascarada por la presencia de hiperparatiroidismo secundario (HPS)<sup>4-6</sup>, lo que dificulta su diagnóstico. En